DDInter405 DDInter1435
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Clofarabine {u} (Compound) resembles {v} (Compound) Adenosine monophosphate
Clofarabine {u} (Compound) resembles {v} (Compound) Nelarabine
Clofarabine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Clofarabine {u} (Compound) treats {v} (Disease) hematologic cancer
Clofarabine {u} (Compound) binds {v} (Gene) DCK
Clofarabine {u} (Compound) upregulates {v} (Gene) FAS
Clofarabine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Clofarabine {u} (Compound) downregulates {v} (Gene) ARL6IP1
Clofarabine {u} (Compound) causes {v} (Side Effect) Escherichia bacteraemia
Clofarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Clofarabine (Compound) resembles Adenosine monophosphate (Compound)
Clofarabine (Compound) resembles Nelarabine (Compound)
Clofarabine may lead to a major life threatening interaction when taken with Cladribine
Clofarabine (Compound) treats hematologic cancer (Disease)
Clofarabine (Compound) binds DCK (Gene)
Clofarabine (Compound) upregulates FAS (Gene)
Clofarabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Clofarabine (Compound) downregulates ARL6IP1 (Gene)
Clofarabine (Compound) causes Escherichia bacteraemia (Side Effect)
Clofarabine may cause a minor interaction that can limit clinical effects when taken with Enoxacin